H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $105 from $70 and keeps a Buy rating on the shares. A recently published peer-reviewed Letter to the Editor in the Journal of Hepatology presented a re-analysis of the Phase II ALXN1840-WD-204 trial, which evaluated copper balance in Wilson disease patients treated with ALXN1840. The letter challenges the sponsor’s earlier findings, arguing they were based on a flawed methodology that considered only urinary and fecal excretion, according to a research note to investors. The re-analysis showed that ALXN1840 actually improved copper balance over the course of the study, the firm reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $85 from $60 at Chardan
- Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler
- Monopar Therapeutics Announces Underwriting Agreement for Stock Sale
- Positive Outlook for Monopar Therapeutics’ ALXN1840 Amid New Copper Balance Findings
- Monopar Therapeutics price target raised to $104 from $87 at BTIG